Lv41
500 积分 2025-03-21 加入
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
4小时前
待确认
Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders
1个月前
已完结
Stability of Several Biochemical Markers of Bone Metabolism
1个月前
已完结
Anti–PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases
2个月前
已完结
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia
5个月前
已完结
CircRNA-based, non-integrated, in vivo panCAR-mediated B cell immune resetting in mouse models and non-human primates
5个月前
已完结
Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers
5个月前
已完结
A Biomarker Assay Validation Approach Tailored to The Context of Use and Bioanalytical Platform
5个月前
已完结
A Biomarker Assay Validation Approach Tailored to The Context of Use and Bioanalytical Platform
5个月前
已关闭
A Biomarker Assay Validation Approach Tailored to The Context of Use and Bioanalytical Platform
5个月前
已关闭
皖公网安备34019202002308
